DDInter740 DDInter849
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Guselkumab
Flecainide {u} (Compound) upregulates {v} (Gene) CDK6
CDK6 {u} (Gene) is upregulated by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Guselkumab
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Norethisterone
Norethisterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Flecainide {u} (Compound) downregulates {v} (Gene) GJA1
GJA1 {u} (Gene) is downregulated by {v} (Compound) Rivaroxaban
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Flecainide {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Rivaroxaban
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Flecainide {u} (Compound) causes {v} (Side Effect) Renal failure
Renal failure {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Guselkumab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oliceridine
Oliceridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clobazam
Clobazam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ethosuximide
Ethosuximide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Guselkumab
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Flecainide (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Flecainide (Compound) downregulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Rivaroxaban (Compound) and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Flecainide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Rivaroxaban (Compound) and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Flecainide (Compound) causes Renal failure (Side Effect) and Renal failure (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Guselkumab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide and Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab